Scotland OKs Glivec and Multaq, denies Yondelis and Valdoxan
This article was originally published in Scrip
Executive Summary
The Scottish Medicines Consortium recently announced that a number of drugs including Novartis's Glivec (imatinib) and Sanofi-Aventis's Multaq (dronedarone) should be available on the Scottish NHS. However, PharmaMar's anticancer Yondelis (trabectedin) and Servier's antidepressant Valdoxan (agomelatine) did not fare so well and were declined for use.